2010-021627-27: A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnormal lipids |
|
|
| Ongoing | 3 | 1424 | Europe, RoW | Tablet, Tredaptive 1000 mg/20 mg modified-release tablets | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP., , Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | Primary Hypercholesterolemia or Mixed Dyslipidemia, High blood cholesterol or high concentration of lipids in the blood., Body processes [G] - Metabolic Phenomena [G03] | | | | |
2006-000569-13: Influence on the coronary Microcirculation and on myocArdial perfusion Reserve of Niaspan given IN addition to simvastatin in diabEtic patients |
|
|
| Ongoing | 3 | 40 | Europe | Tablet | Cardioangiologisches Centrum Bethanien | Diabetic patients at high risk for CVD | | | | |
2005-004218-34: Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins |
|
|
| Ongoing | 3 | 46 | Europe | NIASPAN, NIASPAN, NIASPAN | Department of Cardiology, UK Aachen | coronary artery disease and lipid disorder | | | | |
